KIMADIA Statutory Functions and Direct Import: Supply Chain Entity, Not Approval Authority

1. Key takeaways

KIMADIA’s statutory functions are listed in its own website description as four items. First, to import and market the medicines, scientific appliances, medical and service devices and their spare parts that Iraq needs, except what private law excludes. Second, to conclude contracts and commercial agencies within and outside Iraq. Third, to open warehouses across Iraq. Fourth, to approve agents of civil warehouses and to distribute medicines to civil pharmacies and diagnostic kits to civil laboratories. None of the four functions contains the word approval. Secondary sources consistently state that imports of medical products must pass through a Scientific Bureau registered in Iraq, and that the sole exception is where KIMADIA itself deems direct import necessary. The fork between the public procurement channel and the private channel sits exactly here, because the channel chosen determines three things at once: the declaring entity, the document package and the cash rhythm.

• The four listed functions describe import, marketing, contracting, warehousing and distribution — a supply chain, not an approval chain.
• Secondary sources route medical product imports through registered Scientific Bureaus, with KIMADIA direct import as the sole stated exception.
• Channel classification determines the declaring entity, the document package and the funding rhythm.

2. Legal basis

The sources below set out the functional list and the procurement framework. Their verification status follows the source review.

Source-level note. The functional list is primary and verified. The proposition that imports of medical products must pass through a Scientific Bureau and that the sole exception is KIMADIA direct import obtained no official provision in this review; it is consistently retold by several law firms and consultancies and is classified as secondary, not citable as a statutory provision.

Extracts of the operative provisions. The functional list, in its original English wording, comprises: to take the necessary measures for importing and marketing what Iraq needs of medicines and scientific appliances, medical and service devices and their spare parts, to achieve its purposes, except what is excluded by private law; to enter into contracts and agreements within and outside Iraq for private and commercial agencies; to open stores in parts of Iraq; and to adopt agents of civil stores, with distribution of medicines and medical supplies to civil pharmacies and diagnostic kits to civil laboratories.

Article 1 of Instruction No. 1 of 2025 places state companies executing projects in the investment plan or the current plan within the definition of contracting entity — the primary basis for KIMADIA being bound by the instruction — and its procurement conduct must accordingly follow the unified electronic announcement and tender platform required by Article 8.

3. Expert insights

The four functions sketch a supply chain, not an approval chain. Import and marketing, contracting and agency, warehousing, distribution — joined together, these four segments form one complete supply chain. The legislator configured these functions to secure supply, not to operate a market-access gate. A company that treats KIMADIA as an approval window has mistaken the buyer of a supply chain for the gatekeeper of the market.

The practical meaning of the sole exception is two document packages. Following the secondary-source position, the private channel imports through a Scientific Bureau while the public channel imports directly by KIMADIA where it deems necessary. The same manufacturer’s two business lines — distributing to private terminals versus supplying public tenders — then face different declaring entities and different document-title requirements. GRZAN separates these two lines at the planning stage and does not share one document set between them.

Functional consolidation creates single-buyer risk. Most markets assign import, agency, warehousing and distribution to different entities, so risk is dispersed and replaceable. Iraq merges the four segments into one state company, and the consequence is extremely high buyer concentration: KIMADIA’s payment rhythm, acceptance standards and guarantee rules become the dominant variables of a supplier’s cash flow. The duty prepayment, government-goods release and guarantee extension rules developed in articles 36 to 38 are the funding rules of this very supply chain.

Debunking the claim that all medical devices entering Iraq must pass through KIMADIA. The qualifiers in the original functions text are to achieve its purposes and except what is excluded by private law: KIMADIA imports only the categories within its own purposes, and its distribution function points to the civil pharmacy and civil laboratory channels. Medical devices imported by the private sector through commercial importers and Scientific Bureaus are not on any mandatory KIMADIA route. Writing the primary public channel as the sole market entrance is the origin of this misreading.

Functions and governing law must be read together. The function of concluding contracts and commercial agencies within and outside Iraq is the institutional background to the file-ownership question of article 31: a state company may itself conclude commercial agency relationships, so defining the authorisation boundary and file ownership in an agency arrangement is a substantive matter, not a formality.

4. Practical recommendations

• GRZAN’s first step on an Iraq project is channel classification: confirm whether the client is entering a public tender (KIMADIA as contracting entity) or private distribution (through a Scientific Bureau and commercial importers). The document lists, document titles and funding arrangements of the two channels are not shared.
• For the public channel, treat Instruction No. 1 of 2025 as the mother rule of tender procedure and check every procedural step against its articles; for the private channel, focus on company registration and Scientific Bureau representation.
• In the agency agreement, state expressly that the agent receives only declaration and follow-up authorisation, not ownership of the registration file; list file migration and termination-cooperation obligations in dedicated clauses.
• For projects involving KIMADIA direct import, confirm in writing at the negotiation stage the document title, the duty bearer and the release arrangements, without reusing private-channel templates. Practical estimate: the confirmation should be completed before tendering (no official provision found).
• Use the website functional list as internal training material and unify the message: KIMADIA is a supply chain entity, and the registration authority is the Registration Department of the Technical Affairs Directorate (DTA) at the Ministry of Health.

5. Verification checklist

• □ Connect directly to the KIMADIA About Us page and re-check the four functions in English, confirming no approval-type functional wording.
• □ Search for gazette originals of the Scientific Bureau Instructions No. 4 (1998) and verify whether the through-Scientific-Bureau rule with the sole KIMADIA exception is a provision; if only retold, keep the secondary label.
• □ Check the contracting-entity definition in Article 1 and the platform announcement requirement in Article 8 of Instruction No. 1 of 2025, confirming KIMADIA tenders are covered.
• □ Review KIMADIA website announcements and tabulate the category scope and frequency of direct-import announcements.
• □ Confirm with the client whether the target terminals are the civil pharmacy and civil laboratory channels or the public channel.
• □ Re-check whether the official documents cited here have been replaced by later instructions or decisions (verification baseline date: 29 October 2026).

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com